Professor Stephen Devereux is a Consultant Haematologist based at King's College Hospital in London.  He is also Professor in Lymphoma Biology at King's College London.

Professor Devereus trained in Haematology at the Royal Free and University College London Hospitals where he also worked as a Senior Lecturer.

Professor Devereux has extensive experience in the diagnosis and treatment of blood cancers with a particular interest in lymphoid malignances and chronic lymphatic leukaemia. He plays an active role in both laboratory and clinical research and directs an internationally competitive team working on the biology of lymphoma at King's College London.

Professor Devereux is Clinical Director of the London South Comprehensive Local Research Network and the South East London Cancer Research Network. He is a medical advisor to the Lymphoma Association and serves on the executive of the UK-CLL forum executive, the NCRN CLL subgroup and the Leukaemia and Lymphoma Research Fund Clinical Trials Committee.

Dr Simon Chowdhury is a Consultant Medical Oncologist based at Guy's and St Thomas' NHS Foundation Trust.

Dr Chowdhury was appointed to Guy’s hospital in 2007 to lead the medical oncology group in the treatment of urological cancers.

Dr Chowdhury received his first degree from the University of Cambridge and qualified as a doctor at Guys and St Thomas’ Medical School. He completed his PhD in tumour targeting at University College London. He also trained at St George’s and The Royal Marsden Hospitals. He was a Visiting Fellow at the Dana Farber Cancer Institute in Boston, with which he retains strong links. Between 2000 and 2003. Dr Chowdhury was a Research Fellow for Cancer Research UK.

He is actively involved in clinical trial research into urological cancer, and is a member of the London Kidney Cancer Group which aims to develop further clinical trials in the London area. He is the joint lead for the treatment of urological cancers within the South East London Cancer Network.

He has co-authored over 20 papers in peer-reviewed journals and contributed chapters to six medical texts

Dr Ronald Beaney is a Consultant Clinical Oncologist based at Guys and St. Thomas' NHS Trust in London.

Dr Beaney did his undergraduate training in Scotland followed by posts abroad and in the UK. His oncology training was at the Hammersmith Hospital in London where his MD thesis was on the role of positron emission topography in oncology.

He has been a Consultant Clinical Oncologist attached to Guy's and St Thomas' and King's College Hospitals in London. His major clinical interests lie in tumours of the brain (gliomas) and pelvis (prostate and gynaecological tumours). His current interests are novel drugs for treating tumours and the use of stereotactic radiation, both gamma knife and cyber knife.

Dr Beaney has been on the Faculty Board of the Royal College of Radiologists and an examiner for the same college. He is a Council member of the British neuro-oncology society and a member of the brain tumour working party of the European Organisation for the treatment of Cancer (EORTC) and he is a member of several UK, European and American Cancer Societies and examiner for the Royal College of Radiologists.

Dr Rebecca Kristeleit is Clinical Senior Lecturer and Consultant Medical Oncologist at University College London and University College London Hospitals NHS Foundation Trust.

Dr Kristeleit specialises in the treatment of gynaecological cancers.

Dr Kristeleit qualified in medicine from St Andrew’s and Manchester Universities including eight months at the University of Lausanne (Switzerland) on an Erasmus scholarship. Following general medical training in London, Rebecca undertook her medical oncology training at The Royal Marsden Hospital and a CRUK-funded research fellowship at the Institute of Cancer Research. Subsequently, Rebecca spent a year as a senior research fellow on the Drug Development Unit at the Royal Marsden Hospital gaining specialist experience in the design and conduct of early phase clinical trials and translational medicine.

She also has a specialist interest in drug development as well and is leading several clinical trials of novel agents relevant to gynecological malignancies including PARP inhibitors.

Dr Mark Harries is a Consultant Medical Oncologist based at Guy’s & St Thomas’ Hospitals NHS Foundation Trust and honorary senior lecturer at Kings College London School of Medicine.

Dr Harries specialises in the treatment of Breast Cancer and Melanoma.

Mark graduated from Cambridge University and underwent clinical training at The Royal London Hospital. He trained in Medical Oncology at the Royal Marsden Hospital and completed a PhD and post-doctoral work in the Department of Immunology at University College London.

Dr Harries is a member of the Association of Cancer Physicians, Royal College of Physicians, American Society of Clinical Oncology, European Society of Medical Oncology and the British Medical Association.

Dr Majid Kazmi is a Consultant Haematologist based at Guy’s & St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust.

Dr Kazmi qualified from the University of Aberdeen in 1991 with Commendation. He has been a consultant in Haemato-oncology since 2001. 

Currently Dr Kazmi is the Lead Cancer Clinician and Clinical Director of Oncology & Haematology at Guy’s & St Thomas’.  He is also medical director for commercial activities at the Trust. He is Chair of the Haemato-oncology pathway group on behalf of the London Cancer Alliance covering the population of South London and NW London (5 million people).

His clinical interests include Myeloma where he has been the UK Chief Investigator for a number of national and international studies. He sits on the UK guidelines group for Myeloma and Amyloidosis. He has extensive experience in Transplantation and is the UK lead for transplantation in auto-immune diseases for EBMT (European Group for Blood and Marrow Transplantation).

Dr Kazmi is a member of European group for Blood and Marrow Transplantation (EBMT) and American Society of Haematology (ASH), American Society of Haematology, British Society of Marrow Transplantation and the European Group for Blood and Marrow transplantation.

Dr Lucy Brazil is a Consultant Clinical Oncologist based at Guy's and St Thomas' NHS Foundation Trust.

Dr Brazl has a special interest in neuro-oncology, in particular, the treatment of glioblastoma multiforme and low grade glioma (including oligodendroglioma). She trained in oncology at Royal Marsden Hospital and Guy's and St Thomas’ Hospitals. She was awarded an MD in 2007 for research into breast cancer genetics at the Institue of Cancer Research and Breakthrough Breast Cancer. 

Dr Brazil is an active member of The National Cancer Institute Brain Tumour Clinical Studies Group, as well as The European Organisation for Research and Treatment of Cancer Brain Tumour Group. She is also Chairman of The Brain Tumour Palliative Care / Quality of Life subgroup.

Dr Brazil was Chief investigator for the CODEL brain tumour study using chemotherapy and radiotherapy for Gliomas,

Chairman of the brain tumour Palliative care QOL sub-group, and Systemic Chemotherapy Neuro-oncology Research lead at Guy’s and St Thomas’.

Dr David Landau is a Consultant Clinical Oncologist at Guys and St. Thomas' NHS Trust.

Dr Landau qualified at Charing Cross and Westminster Medical School (now part of Imperial) in 1990. Most of his training in Clinical Oncology was at Charing Cross Hospital and he finished his training with clinical and research posts at The Royal Marsden Hospital.

Dr Landau now specialises only in cancers of the thorax, lung cancers, mesothelioma and thymoma. He also has a specialist interest in metastatic disease from many primaries. He has a particular interest in high-tech radiotherapy treatments.

Dr Landau is one of one founders of London Oncology Clinic in Harley Street and speaks English and French.

Dr David Feuer is a Consultant in Palliative Medicine based at Barts and The London NHS Trust.

Dr Feuer graduated from of The University of Southampton with degrees in Molecular Biology and Medicine. After training in a range of London hospitals, he became Senior Registrar & Research Fellow at The Royal Marsden NHS Trust. In this post he undertook a systematic review of The Management of Intestinal Obstruction due to advanced Gynaecological and Intestinal Cancer, funded by the NHS Executive Research and Development Fund. Numerous papers have resulted from this work, published in the specialist professional literature covering the fields of palliative medicine, general surgery, specialised gynecological oncology, and oncology.

Dr Feuers major interests include pathophysiology and the diagnosis and treatment of malignant intestinal obstruction, together with teaching focusing on the need for critical appraisal of the literature. He is passionate about the need for adequate palliative care and pain relief for all patients at any stage of their illness and  has made many presentations to local, national & international meetings, most notably as invited expert speaker to the NIH meeting in Los Angeles in 2004.

Professor Andrew Tutt is a consultant clinical oncologist based at the Guy’s Hospital Breast Unit and is a Professor of Oncology at King’s College London School of Medicine.

Prof Tutt trained in clinical oncology at the Royal Marsden Hospital London and in breast cancer research at London’s Institute of Cancer Research, where he gained his PhD in Cancer Biology.

Professor Tutt focuses his clinical practice exclusively on breast oncology and its biological, chemotherapy and radiation therapies. He has a particular research interest in “triple negative” and BRCA1 and BRCA2 associated breast cancers where he has led a number of international clinical trials of drug therapies and is the director of a research program focusing on these areas.

Professor Tutt has published and presented a large number of breast cancer research papers and is an invited speaker and session chair at major European and North American Cancer Medicine conferences. He is a member of the St Gallen International Breast Cancer Consensus Panel that develops international breast cancer treatment guidelines and a member of a UK team testing new techniques in breast radiotherapy.

Professor Tutt offers a range of systemic therapy treatments recommended by international guidelines at LOC at London Bridge Hospital and LOC at 95 Harley Street and the radiotherapy at the Harley Street Clinic Cancer Centre and at the Clinical Oncology departments in the Integrated Cancer Centre at Guy’s and St Thomas’s Hospitals near London Bridge and Waterloo Stations.